On the stock market since 2000, it operates in the world of technology. It has 1,091 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (4% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $338.7M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 4 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $4.25 — 102% above today’s price.
A loss of $2.1M against $338.7M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, CRNT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CRNT is a high-risk stock — not yet profitable, and its future rides on its product catching on.